Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients ⁎ ⁎ Data from this study were presented, in part, at the American Diabetes Association, 68th Scientific Sessions, San Francisco, California, June 9–13, 2008 (poster 0533P), and at the 52nd Annual Meeting of the Japan Diabetes Society, Osaka, Japan, May 21–24, 2009 (poster III-P-95).
Titel:
Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients ⁎ ⁎ Data from this study were presented, in part, at the American Diabetes Association, 68th Scientific Sessions, San Francisco, California, June 9–13, 2008 (poster 0533P), and at the 52nd Annual Meeting of the Japan Diabetes Society, Osaka, Japan, May 21–24, 2009 (poster III-P-95).
Auteur:
Horie, Yoshiharu Kanada, Shigeto Watada, Hirotaka Sarashina, Akiko Taniguchi, Atsushi Hayashi, Naoyuki Graefe-Mody, Eva U. Woerle, Hans-Juergen Dugi, Klaus A.